ArticleBMC pediatrics2026
Prognostic role of the neutrophil-to-lymphocyte ratio in pediatric Hodgkin lymphoma: insights from a 20-year single-center experience.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe neutrophil-to-lymphocyte ratio (NLR) is an established prognostic marker in adult malignancies, including Hodgkin lymphoma (HL). However, its clinical significance in pediatric HL remains uncertain due to biological differences and generally favorable outcomes. This study aimed to evaluate the prognostic value of the diagnostic NLR in predicting relapse, refractory disease, and mortality in children with HL. MATERIALS AND
methodsEighty-two patients under 18 years of age who were diagnosed with HL between 2005 and 2025 were retrospectively analyzed. Clinical features, laboratory parameters, treatment response, and survival outcomes were assessed. The NLR was calculated from baseline blood counts obtained before therapy. Receiver operating characteristic (ROC) curve analysis, Kaplan-Meier survival estimates, and logistic regression models were used to determine the prognostic performance of the NLR alongside conventional factors such as stage, B symptoms, albumin, and the erythrocyte sedimentation rate.
resultsThe mean NLR at diagnosis was 3.76 ± 2.77. ROC analysis revealed poor discriminative power (AUC = 0.517, p = 0.822). Event-free survival (EFS) and overall survival (OS) did not differ between the high and low NLR groups (p = 0.870 and p = 0.315, respectively). In the multivariable logistic regression, early two-cycle chemotherapy response remained an independent predictor of adverse outcomes (p = 0.002), whereas bulky disease showed borderline significance (p = 0.059). The NLR and other inflammatory markers, including the ESR and albumin, were not associated with poor prognosis.
conclusionThe diagnostic NLR lacks independent prognostic value in this pediatric HL cohort. These findings highlight the biological distinctness of pediatric disease and suggest that adult-derived inflammatory biomarkers should not be directly extrapolated to childhood malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.